首頁 > 市場調查報告書 > 製藥 > 癌症 > 癌症藥物最新動向：前列腺癌

聯絡我們?

市場調查報告書

癌症藥物最新動向：前列腺癌

Cancer Drug Discoveries: Prostate Cancer

出版商	Espicom Business Intelligence
出版日期	2007年05月	商品編碼	31922
內容資訊	英文 100 PAGES
價格	US $ 1510 Hard Copy US $ 1510 PDF by E-mail (Single User License) US $ 1510 Web Access (Single User License)

簡介
目錄
相關商品

癌症藥物最新動向：前列腺癌 是由出版商Espicom Business Intelligence在2007年05月所出版的。這份英文市場調查報告書包含100 PAGES 價格從美金1510起跳。

簡介

前列腺癌的死亡率是癌症中最高的，美國、歐洲、日本的患者數合計達到每年 120 萬人以上。前列腺癌藥物佔全球癌症藥物比例約為 12％，2004 年的銷售額達到 28 億美元。

提供醫療儀器、藥品相關情報，獲得全球高度評價的英國市調公司 Espicom Business Intelligence，調查分析了前列腺癌藥物最新動態後，出版了一本綜合報告書“Cancer Drug Discoveries: Prostate Cancer”。

報告書內容包括：目前與新治療方法概要、各藥物 SWOT 分析結果、市場現況、至 2012 年的預測等等。報告書含圖表，內容綱要摘記如下：

前列腺癌背景

前列腺癌的概要、對患者的影響
患者統計
患者增加要素（美國、歐洲、日本）

目前療法

放射線療法的 SWOT（優勢、劣勢、機會、風險）分析

賀爾蒙療法

SWOT 分析
各賀爾蒙療法藥物 SWOT 分析與銷售預測
- LHRH 運作劑
- LHRH 拮抗劑
- Anti-androgens（Zoladex、Lupron、其他 5 種）

化學療法

SWOT 分析
Taxotere 的 SWOT 分析與銷售預測

前列腺癌藥物銷售預測

前列腺癌藥物研發

5-α Reductase inhibitors（Proscar、Avodart）
Non-steroidal SORM (selective oestrogen receptor modulator)（Acapodene）

Phase Ⅱ�Ⅲ 的藥物

免疫療法
疫苗科學依據、SWOT 分析、銷售預測
- Provenge（Phase Ⅲ）
- GVAX（Phase Ⅲ）
單株抗體的科學依據與銷售預測
- MLN2704(Phase Ⅱ�Ⅲ）
- MDX-010（Phase Ⅱ）
抗血管形成劑的 SWOT 分析與銷售預測
- Thalidomid(Phase Ⅲ) 他2種
基因治療劑的 SWOT 分析與銷售預測
- Genasense（Phase Ⅱ）
Endothelin receptor antagonists 的科學依據、SWOT 分析、銷售預測
- Xinlay（Phase Ⅲ）
- YM598（Phase Ⅱ）
賀爾蒙治療劑
- Degarelix（Phase Ⅱ）
細胞毒性製劑的 SWOT 分析與銷售預測
- Satraplatin（Phase Ⅲ）
維生素 D 誘導體的科學依據、SWOT 分析、銷售預測
- DN-101（Phase Ⅱ）
- Hectorol（Phase Ⅱ）
Epothilone 誘導體的科學依據、SWOT 分析、銷售預測
- Ixabepilone（Phase Ⅲ）
- KOS-862
Selective apoptotic anti-neoplastic drugs（SAAND）
- OP-461（Phase Ⅰ�Ⅱ）

前列腺癌新藥物銷售預測

終止藥物

市場現況與未來

癌症藥物全球市場

前列腺癌藥物全球市場

主要企業
- AstraZeneca
- Abbott Laboratories
- sanofi-aventis
前列腺癌藥物大型企業（2012 年預測）

參考文獻、用語集

Improvements in screening and diagnosis have led to significant reductions in mortality since the introduction of the prostate-specific antigen (PSA) test in the 1994. Treatment options vary according to age and the stage of cancer including watchful waiting, surgery, site-directed radiation and hormonal therapies. However, there is a high unmet clinical need for advanced PC patients, particularly those resistant to hormonal treatment.

Research is extremely active in this area and new agents with novel modes of action are being evaluated in clinical trials, including vaccines such as Provenge (Dendreon) and GVAX for hormone refractory PC.

Key points

PC is the second leading cause of cancer in men in the US and the third most common cancer worldwide.
Sales of PC drugs generated US$2.7 billion sales in 2004.
In 2003, PhRMA estimated there were 44 compounds in clinical development for the treatment of PC accounting for 11% of oncology research projects in the US.

Questions answered by this chapter include:

What is the principal cause of the market expanding by 55% by 2012?
What impact will the patent expiry of Casodex (AstraZeneca) have?
Why is much interest being expressed in monoclonal antibody therapies MLN2704 (Millennium Pharmaceuticals) and MDX-010 (Medarex)?
The leading PC treatment in 2012 is estimated to be worth nearly US$1 billion a year. What is it and whos developing it?
Vantas (Valera Pharmaceuticals) is expected to be one of the fastest growing LHRH agonists - why?

PROSTATE CANCER (PC)

Key bullet points

BACKGROUND TO PC

What is PC and how does it affect patients?
Patient statistics
- Incidence, diagnosis rates & treatment; now and in the future
Patient growth drivers
- US
- Europe
- Japan

CURRENT TREATMENTS

SWOT analysis of radiotherapy treatments
- Strengths
- Weaknesses
- Opportunities
- Threats

HORMONAL TREATMENT

SWOT analysis of hormonal treatments
- Strengths
- Weaknesses
- Opportunities
- Threats
SWOT analysis of individual hormonal treatments
LHRH agonists
LHRH antagonists
Anti-androgens
- Zoladex (AstraZeneca)
- Strengths
- Weaknesses
- Opportunities
- Threats
- Sales forecasts
Lupron (TAP Pharmaceuticals/generics)
- Strengths
- Weaknesses
- Opportunities
- Threats
- Sales forecasts
Eligard (sanofi-aventis/Astellas Pharma)
- Strengths
- Weaknesses
- Opportunities
- Threats
- Sales forecasts
Viadur (Bayer)
- Strengths
- Weaknesses
- Opportunities
- Threats
- Sales forecasts
Vantas (Valera Pharmaceuticals)
- Strengths
- Weaknesses
- Opportunities
- Threats
- Sales forecasts
Plenaxis (Praecis Pharmaceuticals)
- Strengths
- Weaknesses
- Opportunities
- Threats
- Sales forecasts
Casodex (AstraZeneca)
- Strengths
- Weaknesses
- Opportunities
- Threats
- Sales forecasts

CHEMOTHERAPY

SWOT analysis of chemotherapy
- Strengths
- Weaknesses
- Opportunities
- Threats
SWOT analysis of individual chemotherapy treatments
Taxotere (sanofi-aventis)
- Strengths
- Weaknesses
- Opportunities
- Threats
- Sales forecast
Sales forecast of current PC drugs

RESEARCH & DEVELOPMENT OF PC DRUGS

5-alpha reductase inhibitors
- Proscar (Merck & Co) and Avodart (GlaxoSmithKline)
Non-steroidal SORM (selective oestrogen receptor modulator)
- Acapodene (GTx Inc)
Phase II / III drugs of interest
Immunotherapy
Vaccines
- Scientific rationale
Provenge (Dendreon) - Phase III
- Strengths
- Weaknesses
- Opportunities
- Threats
- Probability of success and sales forecast
GVAX (Cell Genesys) - Phase III
- Strengths
- Weaknesses
- Opportunities
- Threats
- Probability of success and sales forecast
Monoclonal antibodies
- Scientific rationale
MLN 2704 (Millennium Pharmaceuticals) - Phase II / III
- Probability of success and sales forecast
MDX-010 (Medarex) - Phase II
- Probability of success and sales forecast
Anti-angiogenesis agents
- Scientific rationale
Thalidomid (Celgene) - Phase III
- Strengths
- Weaknesses
- Opportunities
- Threats
- Probability of success and sales forecast
Actimid (CC4047; Celgene Corporation) - Phase II
- Probability of success and sales forecast
ZD4054/ZD6474 (AstraZeneca) - Phase II
Gleevec/Glivec (Novartis) - Phase II
Gene therapy
- Scientific rationale
Genasense (Genta) - Phase II
- Strengths
- Weaknesses
- Opportunities
- Threats
- Probability of success and sales forecast
Endothelin receptor antagonists
- Scientific rationale
Xinlay (Abbott Laboratories) - Phase III
- Strengths
- Weaknesses
- Opportunities
- Threats
- Probability of success and sales forecast
YM598 (Astellas Pharma) - Phase II
Hormonal therapies
- Degarelix (Ferring) - Phase II
Cytotoxics
Satraplatin (GPC Biotech/Spectrum Pharmaceuticals) - Phase III
- Scientific rationale
- Strengths
- Weaknesses
- Opportunities
- Threats
- Probability of success and sales forecast
Vitamin D analogues
- Scientific rationale
DN-101 (Novacea) - Phase II
- Probability of success and sales forecast
Hectorol (Bone Care International) - Phase II
Epothilone analogues
Ixabepilone (BMS-247550; Bristol-Myers Squibb) - Phase III
- Strengths
- Weaknesses
- Opportunities
- Threats
- Probability of success and sales forecast
KOS-862 (Kosan/Roche)
Selective apoptotic anti-neoplastic drugs (SAAND)
OP-461 (OSI Pharmaceuticals) - Phase I/II
Sales forecast of new PC drugs

DISCONTINUATION OF DRUGS

THE MARKET - CURRENT AND FUTURE

GLOBAL CANCER MARKET

GLOBAL PC MARKET

Key companies in the PC market
- AstraZeneca
- Abbott Laboratories
- sanofi-aventis
Leading PC companies in 2012E

BIBLIOGRAPHY

GLOSSARY

APPENDIX 1 - US PC DEMOGRAPHICS 2003-2012

APPENDIX 2 - EUROPEAN PC DEMOGRAPHICS 2003-2012

APPENDIX 3 - JAPANESE PC DEMOGRAPHICS 2003-2012

Disclaimer

INDEX OF TABLES

Table 1: TNM classification in prostate cancer
Table 2: Prostate cancer management
Table 3: Current hormonal treatments
Table 4: Average wholesale price of LHRH agonists/antagonists
Table 5: Global PC sales of new products 2004A-2012E (US$ millions)
Table 6: Current PC drugs in clinical development
Table 7: Sales forecasts of new developmental drugs (2004A-2012E)
Table 8: Potential candidates for prostate cancer discontinued from development

INDEX OF CHARTS

Figure 1: Increase in elderly as a % of populations
Figure 2: Cancer incidence rates for men - US 1975-2001
Figure 3: Prostate cancer treatment algorithm
Figure 4: Docetaxel combinations currently in research for HRPC
Figure 5: Docetaxel combinations in androgen-dependent prostate cancer
Figure 6: Expected US launch timescales for prostate cancer therapeutics
Figure 7: Provenge mode of action
Figure 8: MDX-010 mechanism of action
Figure 9: Global oncology market 2004 - US$24 billion
Figure 10: Global PC market by region 2004A - US$2.7 billion
Figure 11: Global PC market by region 2012E - US$8.6 billion
Figure 12: Global PC market by therapy class 2004 - US$2.7 billion
Figure 13: Global PC market by therapy class 2012 - US$8.6 billion
Figure 14: Market share of top five PC players by sales (2004A)
Figure 15: Market share of top 6 PC players by sales (2012E)

簡介
目錄
相關商品

使用指南產品及服務須知網站導覽

星期一到星期五 / 9:30am - 6:00pm
TEL: 02-2729-4219 (+886-2-2729-4219)
E-mail: tw-info@gii.co.jp